# PDC Line Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pdc-line-pharma

- Industry: Biotechnology
- Headquarters: France
- Website: www.pdc-line-pharma.com
- Total disclosed funding: $35M
- Latest round: Series B (Dec 6, 2021)
- Investors on record: 11

## About

Founded in 2014 by founder Laurent LEVY and based in La Tronche, France, PDC Line Pharma SAS developer of a class of off-the-shelf cancer immunotherapies using a proprietary technology called PDCline. In January 2024, PDC Line Pharma SAS received EUR 4.7 million in grant funding from investors Société Régionale d'Investissement de Wallonie and BioWin.
 
PDCline Pharma's core technology is PDCline, a proprietary cell line of plasmacytoid dendritic cells (pDCs). These cells are designed to stimulate a strong immune response against cancer cells. The company product pipeline includes several cancer vaccine candidates: PDCmel for the treatment of melanoma. PDC Mel completed a Phase Ib trial to evaluate its safety and biological activity. PDC lung focused on non-small-cell lung cancer (NSCLC), targets widely expressed shared antigens, and a Phase Ib/II trial is underway to assess its safety and efficacy, both as a monotherapy and in combination with anti-PD-1 immune checkpoint inhibitors. PDC Neo is in the preclinical development stage and targets neoantigens, cancer-specific proteins.
 
The company will use the January 2024 funding to launch the phase I clinical trial of the PDCneo+ vaccine.

## Funding rounds

- Series B, Dec 6, 2021, $13M — Korea Investment Partners, SFPI-FPIM, Sambrinvest, Noshaq, Alpha Holdings, Brain Asset Management, UTC Investment, SRIW
- Series B, Jan 22, 2020, $22M — SFPI-FPIM, Sambrinvest, Shinhan Securities, Noshaq, Financière Spin-Off Luxembourgeoise, UTC Investment, SRIW, AG Investment

## Investors

- SFPI-FPIM — Series B
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series B
- Shinhan Securities (https://capitalatlas.ai/funds/shinhan-securities) — Series B
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series B
- Financière Spin-Off Luxembourgeoise — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B
- SRIW — Series B
- AG Investment (https://capitalatlas.ai/funds/ag-investment) — Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B
- Alpha Holdings — Series B
- Brain Asset Management (https://capitalatlas.ai/funds/brain-asset-management) — Series B